Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity
Treatment with cannabidiol (CBD) or KLS-13019 (novel CBD analog), has previously been shown to prevent paclitaxel-induced mechanical allodynia in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN). The mechanism of action for CBD- and KLS-13019-mediated protection now has been explored with dissociated dorsal root ganglion (DRG) cultures using small interfering RNA (siRNA) to the mitochondrial Na+ Ca2+ exchanger-1 (mNCX-1). Treatment with this siRNA produced a 50–55% decrease in the immunoreactive (IR) area for mNCX-1 in neuronal cell bodies and a 72–80% decrease in neuritic IR area as determined with high-content image analysis. After treatment with 100 nM KLS-13019 and siRNA, DRG cultures exhibited a 75 ± 5% decrease in protection from paclitaxel-induced toxicity; whereas siRNA studies with 10 μM CBD produced a 74 ± 3% decrease in protection. Treatment with mNCX-1 siRNA alone did not produce toxicity. The protective action of cannabidiol and KLS-13019 against paclitaxel-induced toxicity during a 5-h test period was significantly attenuated after a 4-day knockdown of mNCX-1 that was not attributable to toxicity. These data indicate that decreases in neuritic mNCX-1 corresponded closely with decreased protection after siRNA treatment. Pharmacological blockade of mNCX-1 with CGP-37157 produced complete inhibition of cannabinoid-mediated protection from paclitaxel in DRG cultures, supporting the observed siRNA effects on mechanism.
KeywordsSodium-calcium exchanger-1 (NCX-1) Chemotherapy Paclitaxel Cannabidiol siRNA Dorsal root ganglion
Based on the high-content analysis of decreases in mNCX-1 immunoreactive area in DRG neurons, the siRNA approach confirmed the importance of this target in producing acute (5 h) protective actions of CBD and KLS-13019. Coupled with the pharmacological studies, the target knockdown observations suggested that with both cannabinoids, the mNCX-1 target was sufficient to mediate the protection from toxicity produced by paclitaxel in sensory neurons. An unexpected finding was the identification of neuritic mitochondria as a target for the protective action of these cannabinoids. A working hypothesis emerging from these studies is that the cellular location of a target may be of equal importance to the identity of that target, thereby completing or helping to define the mechanistic concept.
These studies were supported by a Grant from the National Institute on Drug Abuse of the National Institutes of Health (R41DA044898).
- Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P, Rissuto R (2009) Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Bioch Biophys Acta 1787:335–344Google Scholar
- Guo L, Hamren J III, Eldridge S, Behrsing HP, Cutuli FM, Mussio J, Davis M (2017) Multiparametric image analysis of rat dorsal root ganglion cultures to evaluate peripheral neuropathy-inducing chemotherapeutics. Tox Sci 156:275–288Google Scholar
- Han Y, Smith MT (2013) Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol 4(156):1–16Google Scholar
- Molinaro P, Sirabella R, Pignataro G, Petrozziello T, Secondo A, Boscia F, Vinciguerra A, Cuomo O, Philipson KD, de Felice M, di Lauro R, di Renzo G, Annunziato L (2016) Neuronal NCX1 overexpression induces stroke resistance while knockout induced vulnerability via Akt. J Cerebral Blood Flow 36:1790–1803CrossRefGoogle Scholar
- Sisalli MJ, Secondo A, Esposito A, Valsecchi V, Savola C, Di Renzo GF et al (2014) Endoplasmic reticulum refilling and mitochondrial calcium extrusion promoted in neurons by NCX1 and NCX3 in ischemic preconditioning are determinant for neuroprotection. Cell Death Differ 21:1142–1149CrossRefGoogle Scholar
- Ward SJ, Riggs D, Tuma R, Kinney WA, Petkanas D, Brenneman DE (2017) Neuroprotective and anti-inflammatory effects of KLS-13019 and cannabidiol in in vitro and in vivo models of chemotherapy-induced neuropathic pain. International Cannabinoid Research Society Symposium, 22 June 2017, Montreal, Canada, 27: P1–40Google Scholar